Open AccessNifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela
Author(s) -
Arturo Muñoz-Calderón,
Zoraida Díaz-Bello,
José Luis Ramı́rez,
Óscar Noya,
Belkisyolé Alarcón de Noya
Publication year - 2019
Publication title -
journal of vector borne diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.581
H-Index - 41
ISSN - 0972-9062
DOI - 10.4103/0972-9062.289397
Subject(s) - nifurtimox , trypanosoma cruzi , outbreak , chagas disease , biology , benznidazole , parasite hosting , population , virology , pharmacology , medicine , veterinary medicine , environmental health , world wide web , computer science
In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were treated with nifurtimox (Lampit®-Bayer), about 70% therapeutic failure was registered. These results led us to examine whether parasite's drug susceptibility was related to this therapeutic failure.